default author photo

Alessandra Boccaccino

University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies

Pisa

Italy

SCHOLARLY PAPERS

2

DOWNLOADS

170

TOTAL CITATIONS

0

Scholarly Papers (2)

Association between sex and response to encorafenib-based combinations in BRAF V600E mutant metastatic colorectal cancer

Number of pages: 30 Posted: 31 Aug 2025
affiliation not provided to SSRN, Vall d'Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Ospedale Santa Chiara - Azienda Ospedaliero Universitaria Pisana
Downloads 68 (929,821)

Abstract:

Loading...

BRAF mutation, Colorectal cancer, Biomarker, Sex, MEK inhibitor, binimetinib

Association between sex and response to encorafenib-based combinations in BRAF V600E mutant metastatic colorectal cancer

Number of pages: 52 Posted: 24 Nov 2025
affiliation not provided to SSRN, Vall d'Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ospedale Santa Chiara - Azienda Ospedaliero Universitaria Pisana, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Medical Oncology 1, Fondazione Policlinico Universitario A. Gemelli IRCCS - Oncologia Medica, University Hospital of Pisa - Unit of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - Department of Medical Oncology, Careggi University Hospital of Florence - Clinical Oncology Unit, Ospedale Santa Chiara - Azienda Ospedaliero Universitaria Pisana, AUSL Romagna - Oncology Unit, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, University Hospital of Pisa - Unit of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO)Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO)
Downloads 27 (1,400,723)

Abstract:

Loading...

BRAF mutation, colorectal cancer, Biomarker, sex, MEK inhibitor, binimetinib

2.

Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population

Number of pages: 28 Posted: 15 May 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Universita di Cagliari - University Hospital of Cagliari, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, IRCCS Humanitas Research Hospital, Università Campus Bio-Medico di Roma, Seoul National University - Seoul National University Bundang Hospital, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, affiliation not provided to SSRN, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Clinico Humanitas, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, University Hospital Frankfurt, University of Foggia, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 75 (837,727)

Abstract:

Loading...

cholangiocarcinoma, durvalumab, immunotherapy, real-world evidence, biliary tract cancer, advanced disease